Sequana Medical raises CHF 23 million

Zurich, Switzerland: 28 April 2014 - Sequana Medical AG, a private Swiss medical device company with innovative fluid management technologies, announced today that it has raised CHF 23 million ($26.2 million) in a Series C preferred share financing round led by LSP (Life Science Partners), and co-led by NeoMed Management, VI Partners, BioMedInvest, Entrepreneurs Fund and Capricorn Venture Partners. NeoMed retains its role as the largest investor in Sequana Medical.

Sequana Medical's alfapump system is a fully implantable battery-powered pump system that automatically and continually moves excess abdominal fluid, called ascites, from the abdominal cavity to the bladder, where it is passed naturally from the body. Refractory ascites is a common complication in patients suffering from liver cirrhosis and certain cancers and affects over 100,000 patients per year in Europe and the US.

More info on the press release or on Sequana's website. 


Next > Mainstay Medical to Euronext and Irish Stock Exchange

Previous > University of Nebraska Medical Center Selects Cartagenia Bench Platform for Ngs and Array Routine Diagnostics